Authored By: Sarah
11 Jul 2024

 Plasma Fractionation Market to grow by USD 10.00 billion between 2024-2028

According to a research report “ Plasma Fractionation Market” by Product (Immunoglobulins, Albumin, Coagulation factor concentrates, Protease inhibitors, Others) Application (Immunology, Neurology, Hematology, Critical care, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 10.00 billion at a CAGR of  6.09% during the forecast period. The expanding prevalence of respiratory disorders, particularly Alpha-1 Antitrypsin Deficiency (AATD), is driving the growth of the global plasma fractionation market. Alpha-1 Antitrypsin (AAT) is a vital protein that shields the lungs from enzyme-induced damage. AATD, a genetic condition characterized by insufficient AAT levels, heightens the risk of lung and liver diseases. Plasma-derived products, including those obtained through fractionation, are utilized in a wide range of therapeutic applications beyond respiratory diseases. The expanding application spectrum fuels market expansion. Moreover, heightened awareness of respiratory diseases, including AATD, and advanced diagnostic techniques facilitate earlier identification of affected individuals..

Browse market data tables, figures, and in-depth TOC on “Plasma Fractionation Market” by Product (Immunoglobulins, Albumin, Coagulation factor concentrates, Protease inhibitors, Others) Application (Immunology, Neurology, Hematology, Critical care, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028.

 View detailed Table of Content- Click here

By Product, the Immunoglobulins segment is projected to dominate the market size in 2024.

In the healthcare industry, the Plasma Fractionation Market experiences significant growth due to the increasing utilization of plasma-derived immunoglobulins for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), and type 1 diabetes. Immunoglobulin therapy plays a crucial role in regulating the immune system and mitigating the effects of autoimmune responses. Furthermore, this therapy is beneficial for individuals with secondary immunodeficiencies caused by HIV/AIDS or specific medical treatments. Key autoimmune disorders, such as immune thrombocytopenia (ITP), rheumatoid arthritis, and systemic lupus erythematosus, are prime targets for immunoglobulin therapy applications. The immunology sector significantly contributes to the expansion of the plasma fractionation market.

By Application, Immunology  segment is expected to hold the largest market size for the year 2024.

In the global plasma fractionation market, immunoglobulins, or antibodies, are key components derived from the process. These proteins, including intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG), are essential therapeutic products. They are used to address primary immunodeficiency disorders, such as HIV, autoimmune diseases, and cancers, where the immune system fails to produce adequate antibodies. By providing patients with a consistent supply of immunoglobulins, these treatments bolster their immune systems and aid in the fight against infections.

North America is forecasted to hold the largest market size by region in 2024.

The North American plasma fractionation market is projected to experience steady expansion, driven by significant demand in the US, Canada, and Mexico. These countries' robust plasma collection infrastructure and culture of voluntary donation ensure a reliable plasma source. Factors fueling growth include the rise in surgical procedures, increasing blood donor base, and escalating cancer prevalence. Additionally, government and NGO end-use sectors' expanding requirements contribute to market expansion.

The Plasma Fractionation Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • ADMA Biologics Inc.
  • Bharat Serums and Vaccines Ltd.
  • CSL Ltd.
  • Emergent BioSolutions Inc.
  • GC Biopharma corp. 
  • Grifols SA
  •  Hemarus Plasma
  • Intas Pharmaceuticals Ltd.
  • Kamada Ltd.
  • Kedrion S.p.A
  • LFB SA
  • Merck KGaA
  • Mitsubishi Chemical Group Corp.
  • Octapharma AG
  • PlasmaGen BioSciences Pvt. Ltd.
  • Prothya Biosolutions Netherlands BV
  • Sanquin
  • SK Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Virchow Laboratories Ltd.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Plasma Fractionation Market encompasses the production and sale of various therapeutic proteins derived from plasma, including Thrombin and Prothrombin complex. These factors play crucial roles in the coagulation cascade and are essential for managing anticoagulant imbalances in chronic disorders and rare diseases, such as primary immunodeficiencies and liver diseases. Plasma collection centers serve as vital sources of raw material for this industry, with plasma being fractionated through advanced techniques to yield immunoglobulins, albumins, and other therapeutic proteins. These products find extensive applications in the treatment of various therapeutic areas, including respiratory diseases like emphysema and lung diseases, as well as thrombotic conditions. The Plasma Industry continues to grow, driven by the increasing demand for these life-saving therapies.

Market Research Overview

The Plasma Fractionation Market encompasses a broad spectrum of industries and applications, including clinical research laboratories specializing in Immunology & neurology. This market involves the production of various therapeutic products, such as Factor VIII, Factor IX, Subcutaneous Immunoglobulin (SCIG), and Intravenous Immunoglobulin (IVIG), used in the treatment of Hemophilia, Hepatic disorders, Neurological disorders, Immunological disorders, and other chronic disorders, particularly in the therapeutic areas of Pulmonology, Critical care, Hematology, Immunology, Neurology, Rheumatology, Hemato-oncology, and Coagulation factor concentrates. Plasma fractionation technologies are employed by small, mid-sized, and large companies to process raw material supply from Plasma donations through Plasmapheresis and Plasma collection. Automation plays a crucial role in Plasma fractionation processes, ensuring the production of high-quality Plasma-derived factors, such as Anticoagulant factors, Albumins, and Recombinant factors like Alpha-1-antitrypsin. Regulatory authorities, including the WHO and various national bodies, strictly enforce guidelines to ensure the safety and efficacy of these therapies, addressing concerns related to Blood-borne pathogens.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio
Document